Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

BLOOD COMMENTARIES

HOW I TREAT

Biguzzi and colleagues use 5 illustrative cases to present their approach to gastrointestinal bleeding in the setting of congenital and acquired von Willebrand disease, stressing the importance of endoscopic evaluation, the role of arteriovenous malformations, and therapy with rescue therapies and iron supplementation.

CLINICAL TRIALS AND OBSERVATIONS

The authors analyzed the outcomes of an international cohort of 198 patients with symptomatic COVID-19 and chronic lymphocytic leukemia (CLL), demonstrating a case fatality rate of 33%. Outcomes were similar in treatment-naïve and treated patients. Treatment with Bruton tyrosine kinase (BTK) inhibitors did not appear to affect survival, though it was held in most patients with symptomatic disease.

HEMATOPOIESIS AND STEM CELLS

Sca-1 positivity has been traditionally used as a marker for hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs). While it is meaningful in steady-state conditions, Kanayama and colleagues demonstrated that inflammation upregulates Sca-1 expression on lineage committed cells, and that CD86 expression is a better means for distinguishing HSCs/MPPs from committed progenitors. This will facilitate future investigations of the dynamics of stress hematopoiesis.

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Proliferation of many hematologic and solid malignancies is driven partly through catabolism of arginine, creating an arginine-deficient extracellular milieu. Since T cells express very low levels of arginine resynthesis enzymes, they proliferate poorly in low levels of arginine. Engineering chimeric antigen receptor (CAR) T cells to also express arginosuccinate synthase or ornithine transcarbamylase improves CAR T-cell proliferation without loss of efficiacy.

LYMPHOID NEOPLASIA

Tulstrup et al used genome-wide association studies to identify germline variants that modulate methotrexate metabolism, explaining interpatient variability in methotrexate response.

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

The authors report that neutrophil extracellular traps (NETs) are increased in patients with severe COVID-19, and are induced in normal neutrophils by exposure to plasma from patients infected with SARS-CoV-2. Autopsy studies of lungs from patients succumbing to COVID-19 showed abundant NET-containing microthrombi and extensive neutrophil and platelet infiltration, suggesting that NET-triggered immunothrombosis may be central to the thrombotic complications of COVID-19.

PLATELETS AND THROMBOPOIESIS

Rap1 plays an important role in multiple aspects of platelet function, including talin-1 binding to activate integrins, as well as thrombopoiesis, platelet secretion, and surface expression of phosphatidylserine. Lagarrigue et al investigated the interaction of talin-1 and Rap1, demonstrating that Rap1–talin-1 interaction is required for platelet integrin activation but not for other Rap1-mediated platelet functions.

RED CELLS, IRON, AND ERYTHROPOIESIS

Decreased microvascular blood flow (MBF) predisposes to vasocclusion by sickled red blood cells. The authors demonstrate that sequential thermal stimulation of one hand decreases MBF in the contralateral hand in both sickle cell disease (SCD) patients and normal controls. However, SCD patients had augmented and progressive decreases in blood flow relative to controls, likely providing a link between environmental cold and heat exposure and SCD vaso-occlusive crisis.

TRANSPLANTATION

Robert Chiesa,for the EBMT Inborn Errors Working Party,Junfeng Wang,for the EBMT Inborn Errors Working Party,Henric-Jan Blok,for the EBMT Inborn Errors Working Party,Sheree Hazelaar,for the EBMT Inborn Errors Working Party,Benedicte Neven,for the EBMT Inborn Errors Working Party,Despina Moshous,for the EBMT Inborn Errors Working Party,Ansgar Schulz,for the EBMT Inborn Errors Working Party,Manfred Hoenig,for the EBMT Inborn Errors Working Party,Fabian Hauck,for the EBMT Inborn Errors Working Party,Amal Al Seraihy,for the EBMT Inborn Errors Working Party,Jolanta Gozdzik,for the EBMT Inborn Errors Working Party,Per Ljungman,for the EBMT Inborn Errors Working Party,Caroline A. Lindemans,for the EBMT Inborn Errors Working Party,Juliana F. Fernandes,for the EBMT Inborn Errors Working Party,Krzysztof Kalwak,for the EBMT Inborn Errors Working Party,Brigitte Strahm,for the EBMT Inborn Errors Working Party,Urs Schanz,for the EBMT Inborn Errors Working Party,Petr Sedlacek,for the EBMT Inborn Errors Working Party,Karl-Walter Sykora,for the EBMT Inborn Errors Working Party,Serap Aksoylar,for the EBMT Inborn Errors Working Party,Franco Locatelli,for the EBMT Inborn Errors Working Party,Polina Stepensky,for the EBMT Inborn Errors Working Party,Robert Wynn,for the EBMT Inborn Errors Working Party,Su Han Lum,for the EBMT Inborn Errors Working Party,Marco Zecca,for the EBMT Inborn Errors Working Party,Fulvio Porta,for the EBMT Inborn Errors Working Party,Mervi Taskinen,for the EBMT Inborn Errors Working Party,Brenda Gibson,for the EBMT Inborn Errors Working Party,Susanne Matthes,for the EBMT Inborn Errors Working Party,Musa Karakukcu,for the EBMT Inborn Errors Working Party,Mathias Hauri-Hohl,for the EBMT Inborn Errors Working Party,Paul Veys,for the EBMT Inborn Errors Working Party,Andrew R. Gennery,for the EBMT Inborn Errors Working Party,Giovanna Lucchini,for the EBMT Inborn Errors Working Party,Matthias Felber,for the EBMT Inborn Errors Working Party,Michael H. Albert,for the EBMT Inborn Errors Working Party,Dmitry Balashov,for the EBMT Inborn Errors Working Party,Arjan Lankester,for the EBMT Inborn Errors Working Party,Tayfun Güngör,for the EBMT Inborn Errors Working Party,Mary A. Slatter,for the EBMT Inborn Errors Working Party

The authors report on a retrospective multicenter analysis of 712 patients who had undergone transplantation for chronic granulomatous disease (CGD) between 1993 and 2018. Overall survival is excellent, although best for younger patients receiving family donor transplants. Given the long-term infectious and inflammatory morbidity and mortality of this rare immunodeficiency syndrome, the data support early allogeneic transplantation for CGD.

BLOOD WORK

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals